Letairis® (Ambrisentan) was approved by the US FDA for the treatment of pulmonary artertial hypertension (PAH) in June 2007, for people with WHO class II or III symptoms. It relaxes blood vessels and improves circulation, thus improving exercise capacity and delaying worsening. It is a pill which is taken once a day. Usually people are started at 5mg and if that is well tolerated, it is increased to 10mg. (Also see Pulmonary Involvement, Pulmonary Hypertension, and PH/PAH Treatments)
Letairis Support. Patient assistance program and pharmacy access. Unlike many other medicines, Letairis is not available at your local retail pharmacy. Instead, Letairis will be mailed directly to your home. Gilead.
Letairis (ambrisentan) Prescribing Information. Letairis safety, side effects, and prescribing information. Gilead.
Letairis (ambrisentan) is a potent type-A selective endothelin receptor antagonist. Endothelin is a peptide made by the body in the endothelium. It constricts blood vessels and elevates blood pressure. Endothelin receptor antagonists (ETRAs) are a class of drugs which prevent the constriction or narrowing of blood vessels thereby enhancing blood flow throughout the body. CenterWatch.
The combination of Letairis and Tadalafil reduced risk of progression by 50 percent in PAH WHO Group 1, compared to either therapy alone.
Tadalafil (ADCIRCA®) is FDA approved for the treatment of pulmonary arterial hypertension (PAH). It is a pill that is taken once a day, and can improve exercise ability in PAH. It is manufactured by Eli Lilly and Company, and marketed by Lung Biotechnology PBC, which is a wholy-owned subsidiary of United Therapeutics Corporation. Lung Biotechnology PBC.
U.S. Food and Drug Administration Approves New Treatment Combination of Gileadís Letairis® with Tadalafil for Pulmonary Arterial Hypertension (WHO Group 1). First-Line Combination of Letairis and Tadalafil Reduced Risk of Disease Progression by Nearly 50 Percent Compared to Either Therapy Individually in Study of 605 PAH Patients with WHO Functional Class II-III Symptoms. Gilead, 10/02/2015.
SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses.
We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: